Floatz logo

Megestrol Acetate Impurity B

HIV Wasting Syndrome

Endo USA Inc., a Keenova Therapeutics CompanySmall moleculePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HIV Wasting Syndrome cohort.

Asset / SponsorPhaseRating
2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 4BB
Serostim
EMD Serono
Phase 3B
Testosterone Undecylate
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2B
Atazanavir
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD
Lopinavir
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD
NEVIRAPINE ANHYDROUS
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD
NORVIR
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD
Abacavir
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD

Same molecule, other indications

Megestrol Acetate Impurity B is also rated in:

breast carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
cancer of unknown primary siteDormant
BB
Indicative · Phase 3
66 / 100
View asset →
HIV infectious diseaseDormant
B
Indicative · Phase 2
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →